When to Start Antiplatelets and Anticoagulants After Tenecteplase for MI
Start aspirin immediately with tenecteplase administration (160-325 mg on day 1), and initiate dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) as soon as possible, continuing for at least 12 months. 1
Immediate Administration (With Thrombolysis)
Aspirin should be given on day 1 of acute MI and continued indefinitely. The 2025 ACC/AHA guidelines clearly recommend dual antiplatelet therapy for all patients with acute coronary syndromes 1. There is no waiting period after tenecteplase - antiplatelet therapy is part of the initial management strategy, not a delayed intervention.
Specific Antiplatelet Regimen:
- Aspirin: 160-325 mg immediately, then daily indefinitely 2
- P2Y12 inhibitor: Start as soon as possible
Anticoagulation Timing
Anticoagulation with heparin should be administered concurrently with tenecteplase in specific high-risk situations:
- Patients undergoing primary PCI or surgical revascularization
- Patients at high risk for systemic embolization (e.g., large anterior MI, left ventricular thrombus, atrial fibrillation) 2
The FDA label for tenecteplase does not mandate a delay before starting anticoagulation 3. The bleeding risk from tenecteplase is inherent to the drug itself, not specifically related to timing of adjunctive antithrombotic therapy.
Critical Clinical Context
Why No Delay is Needed:
The pathophysiology of MI involves ongoing platelet activation and thrombosis even during thrombolytic therapy 4. Thrombolytic agents paradoxically activate platelets - tenecteplase itself has been shown to affect platelet function, though it has more profound antiplatelet properties than alteplase 5. This means antiplatelet therapy is complementary, not redundant, and delays would be counterproductive.
Common Pitfall to Avoid:
Do not wait 24 hours to start antiplatelets after tenecteplase. This outdated practice stems from confusion with stroke protocols. In MI, the evidence supports immediate dual antiplatelet therapy. The 2025 guidelines make no mention of delaying antiplatelet therapy after fibrinolysis 1, 6.
Bleeding Risk Management:
While tenecteplase increases bleeding risk 3, this is managed by:
- Avoiding intramuscular injections
- Monitoring for bleeding
- Using proton pump inhibitors in patients at risk for GI bleeding 1
- Not by delaying necessary antiplatelet therapy
Transfer and PCI Considerations:
After tenecteplase administration, patients should be transferred to a PCI-capable center for rescue or elective PCI 6, 3. The antiplatelet regimen remains unchanged - continue dual antiplatelet therapy through and after PCI, with ticagrelor or prasugrel preferred over clopidogrel 1.
Long-term Anticoagulation:
If long-term oral anticoagulation is needed (e.g., atrial fibrillation, left ventricular thrombus), discontinue aspirin 1-4 weeks after PCI and continue P2Y12 inhibitor (preferably clopidogrel) with the anticoagulant to reduce bleeding risk 1.